Entropy Technologies LP Purchases Shares of 11,637 Moderna, Inc. (NASDAQ:MRNA)

Entropy Technologies LP acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 11,637 shares of the company’s stock, valued at approximately $778,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the second quarter valued at approximately $26,000. Cedar Wealth Management LLC increased its stake in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Family Firm Inc. acquired a new position in Moderna in the 2nd quarter valued at $33,000. Bank & Trust Co purchased a new stake in shares of Moderna during the 2nd quarter worth $36,000. Finally, Hanseatic Management Services Inc. purchased a new stake in shares of Moderna during the 2nd quarter worth $48,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Down 5.6 %

MRNA opened at $39.77 on Friday. Moderna, Inc. has a twelve month low of $38.76 and a twelve month high of $170.47. The firm has a market cap of $15.30 billion, a P/E ratio of -7.14 and a beta of 1.69. The business has a 50 day moving average price of $59.96 and a 200 day moving average price of $97.80. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the previous year, the business posted ($1.39) earnings per share. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -9.34 EPS for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. TD Cowen decreased their price objective on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Leerink Partners reduced their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Finally, Sanford C. Bernstein started coverage on shares of Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $93.18.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 2,930 shares of company stock worth $217,170 over the last three months. Company insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.